Stem Point Capital LP Autolus Therapeutics PLC Transaction History
Stem Point Capital LP
- $340 Billion
- Q2 2024
A detailed history of Stem Point Capital LP transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Stem Point Capital LP holds 2,662,732 shares of AUTL stock, worth $10.6 Million. This represents 2.72% of its overall portfolio holdings.
Number of Shares
2,662,732
Previous 2,965,721
10.22%
Holding current value
$10.6 Million
Previous $18.9 Billion
51.03%
% of portfolio
2.72%
Previous 5.0%
Shares
3 transactions
Others Institutions Holding AUTL
# of Institutions
115Shares Held
167MCall Options Held
34.2KPut Options Held
19.5K-
Syncona Portfolio LTD Guernsey, Channel Islands, X021.3MShares$85 Million86.45% of portfolio
-
Blackstone Inc New York, NY20.5MShares$81.5 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA17.9MShares$71.2 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$60.8 Million1.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$49.1 Million0.59% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $362M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...